Effect of the use of low and high potency statins and sepsis outcomes
| Autor: | Shuo Ming Ou, Hsi Chu, Pei Wen Chao, Shu Yu Ou, Szu Yuan Li, Yi Jung Lee, Shu-Chen Kuo, Chia Jen Shih, Yung Tai Chen |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Statin National Health Programs medicine.drug_class Pain medicine Taiwan Comorbidity Kaplan-Meier Estimate Critical Care and Intensive Care Medicine Risk Assessment Sepsis Insurance Claim Review Anesthesiology medicine Potency Humans cardiovascular diseases Hospital Mortality Intensive care medicine Propensity Score Aged Proportional Hazards Models business.industry nutritional and metabolic diseases medicine.disease Outcome and Process Assessment Health Care lipids (amino acids peptides and proteins) Female Hydroxymethylglutaryl-CoA Reductase Inhibitors business |
| Zdroj: | Intensive care medicine. 40(10) |
| ISSN: | 1432-1238 |
| Popis: | Although statins have been shown to have cholesterol-lowering effects, their pleiotropic benefits on sepsis remain a matter of debate. In addition, the influence of statin potency on sepsis-related mortality has never been explored. The aim of our study was to determine the sepsis outcomes of low- and high-potency statin users and non-users.This nationwide, population-based, propensity score-matched analysis used data from the linked administrative databases of Taiwan's National Health Insurance program. Patients were hospitalized for sepsis between 2000 and 2010. All-cause mortality and major adverse consequences of sepsis, such as in-hospital death, intensive care unit admission, shock events, and the use of mechanical ventilation, were assessed. Patients were divided into high-potency statin users (at least 10 mg rosuvastatin, at least 20 mg atorvastatin, or at least 40 mg simvastatin), low-potency statin users (all other statin treatments), and non-users.A propensity score-matched cohort of 27,792 statin users and 27,792 non-users was included. Of 27,792 statin users, 9,785 (35.2 %) were treated with high-potency statins and 18,007 (64.8 %) were treated with low-potency statins. The 1-year mortality risk was significantly lower among both low-potency [adjusted hazard ratio (aHR) 0.89, 95 % confidence interval (CI) 0.85-0.93] and high-potency (aHR 0.80, 95 % CI 0.75-0.86) statin users compared with non-users. The risks of mortality and adverse consequences of sepsis were lower among high-potency than among low-potency statin users.High-potency statin use is associated with a lower risk of sepsis-related mortality compared with low-potency statin use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink